Biomea Fusion Inc (BMEA)

$5.16

-0.16

(-3.01%)

Market is closed - opens 7 PM, 19 Jul 2024

Performance

  • $5.05
    $5.43
    $5.16
    downward going graph

    2.13%

    Downside

    Day's Volatility :7.0%

    Upside

    4.97%

    downward going graph
  • $3.83
    $23.07
    $5.16
    downward going graph

    25.78%

    Downside

    52 Weeks Volatility :83.4%

    Upside

    77.63%

    downward going graph

Returns

PeriodBiomea Fusion IncSector (Health Care)Index (Russel 2000)
3 Months
-52.33%
8.7%
0.0%
6 Months
-62.48%
8.0%
0.0%
1 Year
-75.83%
14.0%
0.0%
3 Years
-60.68%
17.0%
-18.2%

Highlights

Market Capitalization
201.3M
Book Value
$3.77
Earnings Per Share (EPS)
-3.55
Wall Street Target Price
26.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-60.99%
Return On Equity TTM
-116.52%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-135.5M
Diluted Eps TTM
-3.55
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.09
EPS Estimate Next Year
-3.44
EPS Estimate Current Quarter
-0.99
EPS Estimate Next Quarter
-1.09

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Biomea Fusion Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
13
12
Hold
2
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 403.88%

Current $5.16
Target $26.00

Technicals Summary

Sell

Neutral

Buy

Biomea Fusion Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biomea Fusion Inc
Biomea Fusion Inc
9.69%
-62.48%
-75.83%
-60.68%
-71.4%
Moderna, Inc.
Moderna, Inc.
-6.91%
25.22%
1.18%
-60.44%
769.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.48%
16.73%
49.42%
85.5%
258.18%
Novo Nordisk A/s
Novo Nordisk A/s
-3.82%
25.91%
69.01%
206.62%
460.98%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.51%
12.79%
36.04%
145.12%
174.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biomea Fusion Inc
Biomea Fusion Inc
NA
NA
NA
-4.09
-1.17
-0.61
NA
3.77
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.36
32.36
1.46
44.28
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.75
31.75
0.53
17.06
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biomea Fusion Inc
Biomea Fusion Inc
Buy
$201.3M
-71.4%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
769.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$120.7B
258.18%
32.36
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
460.98%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.2B
174.23%
31.75
39.46%

Insights on Biomea Fusion Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 69.0% return, outperforming this stock by 144.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 205.5% return, outperforming this stock by 266.6%

Institutional Holdings

  • FMR Inc

    14.90%
  • State Street Corporation

    12.48%
  • Cormorant Asset Management, LLC

    9.93%
  • LAURION CAPITAL MANAGEMENT LP

    7.57%
  • Baker Bros Advisors LP

    5.87%
  • BlackRock Inc

    5.49%

Company Information

biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro

Organization
Biomea Fusion Inc
Employees
110
CEO
Mr. Thomas Andrew Butler
Industry
Healthcare

FAQs